UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class: |
| Trading Symbol(s) |
| Name of Each Exchange on which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 27, 2024, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
| |
Number | Exhibit Description | |
99.1 | ||
104 | The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on February 27, 2024, formatted in Inline XBRL. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ACLARIS THERAPEUTICS, INC. | ||
Date: February 27, 2024 | By: | /s/ Kevin Balthaser |
Kevin Balthaser |
3
Exhibit 99.1
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.
“As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returning to the CEO role, I look forward to building on our strong foundation and deep expertise in kinase discovery and development as we look to shape the future of Aclaris.”
Research and Development Highlights:
· | ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor |
| o | In January 2024, Aclaris reported positive top-line results from its Phase 2b trial in atopic dermatitis, and is currently seeking a development and commercialization partner for this program. |
· | ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor |
| o | Aclaris is assessing the most effective development pathway, including the lead indication, for ATI-2138. Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023. |
· | Zunsemetinib (ATI-450), an investigational oral small molecule MK2 inhibitor |
| o | Aclaris plans to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer. Aclaris expects these trials to be primarily funded by grants awarded to Washington University. |
| o | ATI-2231, Aclaris’ second MK2 inhibitor, was previously being developed for oncology and Aclaris was supporting Washington University in an investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies. However, Aclaris and Washington University agreed to instead study zunsemetinib in oncology in order to expedite the development timeline by eliminating the need to conduct the Phase 1a trial due to zunsemetinib’s more advanced clinical package. |
· | Discovery |
| o | Aclaris plans to continue to advance discovery programs through KINect®, its proprietary drug discovery platform. |
Financial Highlights:
Liquidity and Capital Resources
As of December 31, 2023, Aclaris had aggregate cash, cash equivalents and marketable securities of $181.9 million compared to $229.8 million as of December 31, 2022.
Financial Results
Fourth Quarter 2023
| ● | Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. |
| ● | Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022. The increase was primarily driven by a one-time upfront payment under the license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma) received in the fourth quarter of 2023. |
| ● | Research and development (R&D) expenses were $26.6 million for the quarter ended December 31, 2023 compared to $21.1 million for the prior year period. The $5.5 million increase was primarily the result of an increase in expenses associated with drug candidate manufacturing for zunsemetinib. |
| ● | General and administrative (G&A) expenses were $8.2 million for the quarter ended December 31, 2023 compared to $7.1 million for the corresponding prior year period. The increase was primarily due to an increase in personnel and stock-based compensation expenses. |
| ● | Licensing expenses were $5.7 million for the quarter ended December 31, 2023 compared to $0.6 million for the prior year period. The increase was primarily attributable to amounts payable to third parties in connection with amounts earned under the Sun Pharma license agreement. |
| ● | Revaluation of contingent consideration resulted in a $26.3 million gain for the quarter ended December 31, 2023 compared to a charge of $7.1 million for the prior year period. |
| ● | Intangible asset impairment charges were $6.6 million for the quarter ended December 31, 2023, representing the full balance of the in-process research and development (IPR&D) intangible asset. The impairment charge resulted from Aclaris’ decision to discontinue further development of the drug candidate for immuno-inflammatory diseases. |
Full Year 2023
| ● | Net loss was $88.5 million for the year ended December 31, 2023 compared to $86.9 million for the year ended December 31, 2022. |
| ● | Total revenue was $31.2 million for the year ended December 31, 2023 compared to $29.8 million for the year ended December 31, 2022. The increase was primarily driven by a one-time upfront payment under the license agreement with Sun Pharma received in the year ended December 31, 2023. The increase was partially offset by both a one-time upfront payment received under a license agreement with Eli Lilly and Company and a one-time upfront payment received under a license agreement with Pediatrix Therapeutics, Inc. in the year ended December 31, 2022. |
| ● | R&D expenses were $98.4 million for the year ended December 31, 2023 compared to $77.8 million for the prior year period. |
| o | The $20.6 million increase was primarily the result of higher: |
| ◾ | Zunsemetinib development expenses, including costs associated with clinical activities for the Phase 2b trial for rheumatoid arthritis and drug candidate manufacturing costs; |
| ◾ | ATI-2138 development expenses, including costs associated with the Phase 1 MAD trial and other preclinical activities; and |
| ◾ | Compensation-related expenses due to an increase in headcount. |
| ● | G&A expenses were $32.4 million for the year ended December 31, 2023 compared to $25.1 million for the prior year period. |
| o | The $7.3 million increase was primarily the result of higher compensation-related costs due to increased headcount and the impact of equity awards granted during the year ended December 31, 2023. |
| o | Bad debt expense recorded from Aclaris’ determination that collection of amounts due from EPI Health are uncertain as a result of their filing for Chapter 11 bankruptcy protection also contributed to the increase. |
| ● | Revaluation of contingent consideration resulted in a $26.9 million gain for the year ended December 31, 2023 compared to a charge of $4.7 million for the corresponding prior year period. |
| ● | Intangible asset impairment charges were $6.6 million for the year ended December 31, 2023,representing the full balance of the IPR&D intangible asset. The impairment charge resulted from Aclaris’ decision to discontinue further development of the drug candidate for immuno-inflammatory diseases. |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans for its development programs, including its plans to seek a development and commercialization partner for ATI-1777 and its strategic review of its business. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2023, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics, Inc.
Consolidated Statements of Operations
(unaudited, in thousands, except share and per share data)
| | Three Months Ended | | Year Ended | | ||||||||
| | December 31, | | December 31, | | ||||||||
|
| 2023 |
| 2022 |
| 2023 |
| 2022 | | ||||
Revenues: | | | | | | | | | | | | | |
Contract research | | $ | 566 | | $ | 866 | | $ | 3,035 | | $ | 4,395 | |
Licensing | | | 17,004 | | | 6,722 | | | 28,214 | | | 25,100 | |
Other | | | — | | | 165 | | | — | | | 257 | |
Total revenue | | | 17,570 | | | 7,753 | | | 31,249 | | | 29,752 | |
| | | | | | | | | | | | | |
Costs and expenses: | | | | | | | | | | | | | |
Cost of revenue (1) | | | 725 | | | 877 | | | 3,423 | | | 4,023 | |
Research and development (1) | | | 26,646 | | | 21,072 | | | 98,384 | | | 77,813 | |
General and administrative (1) | | | 8,214 | | | 7,146 | | | 32,412 | | | 25,133 | |
Licensing | | | 5,703 | | | 637 | | | 14,658 | | | 7,937 | |
Revaluation of contingent consideration | | | (26,300) | | | 7,100 | | | (26,900) | | | 4,700 | |
Intangible asset impairment | | | 6,629 | | | — | | | 6,629 | | | — | |
Total costs and expenses | | | 21,617 | | | 36,832 | | | 128,606 | | | 119,606 | |
Loss from operations | | | (4,047) | | | (29,079) | | | (97,357) | | | (89,854) | |
Other income, net | | | 2,189 | | | 1,444 | | | 8,509 | | | 2,946 | |
Loss before income taxes | | | (1,858) | | | (27,635) | | | (88,848) | | | (86,908) | |
Income tax benefit | | | (367) | | | — | | | (367) | | | — | |
Net loss | | $ | (1,491) | | $ | (27,635) | | $ | (88,481) | | $ | (86,908) | |
Net loss per share, basic and diluted | | $ | (0.02) | | $ | (0.41) | | $ | (1.27) | | $ | (1.33) | |
Weighted average common shares outstanding, basic and diluted | | | 70,866,315 | | | 66,685,580 | | 69,808,855 | | | 65,213,944 | | |
| | | | | | | | | | | | | |
(1) Amounts include stock-based compensation expense as follows: | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Cost of revenue | | $ | 337 | | $ | 314 | | $ | 1,456 | | $ | 1,151 | |
Research and development | | | (2,367) | | | 1,517 | | | 6,801 | | | 3,745 | |
General and administrative | | | 3,296 | | | 2,982 | | | 12,285 | | | 10,143 | |
Total stock-based compensation expense | | $ | 1,266 | | $ | 4,813 | | $ | 20,542 | | $ | 15,039 | |
Aclaris Therapeutics, Inc.
Selected Consolidated Balance Sheet Data
(unaudited, in thousands, except share data)
|
| December 31, 2023 |
| December 31, 2022 |
| ||
Cash, cash equivalents and marketable securities | | $ | 181,877 | | $ | 229,813 | |
Total assets | | $ | 197,405 | | $ | 254,596 | |
Total current liabilities | | $ | 30,952 | | $ | 21,938 | |
Total liabilities | | $ | 40,226 | | $ | 56,975 | |
Total stockholders' equity | | $ | 157,179 | | $ | 197,621 | |
Common stock outstanding | | | 70,894,889 | | | 66,688,647 | |
Aclaris Therapeutics, Inc.
Selected Consolidated Cash Flow Data
(unaudited, in thousands)
|
| Year Ended |
| Year Ended |
| ||
| | December 31, 2023 | | December 31, 2022 | | ||
Net loss | | $ | (88,481) | | $ | (86,908) | |
Depreciation and amortization | | | 863 | | | 797 | |
Stock-based compensation expense | | | 20,542 | | | 15,039 | |
Revaluation of contingent consideration | | | (26,900) | | | 4,700 | |
Intangible asset impairment charge | | | 6,629 | | | — | |
Deferred taxes | | | (367) | | | — | |
Changes in operating assets and liabilities | | | 9,389 | | | (1,195) | |
Net cash used in operating activities | | $ | (78,325) | | $ | (67,567) | |
Aclaris Therapeutics Contact:
investors@aclaristx.com
